CFO
ANIP icon

Collective Family Office’s ANI Pharmaceuticals ANIP Stock Holding History

Collective Family Office’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,182
Closed -$213K – 169
2022
Q2 		$213K Sell
7,182
-1,043
-13% -$30.1K 0.09% 178
2022
Q1 		$231K Buy
8,225
+3,000
+57% +$112K 0.09% 175
2021
Q4 		$241K Buy
+5,225
New +$225K 0.09% 167

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Collective Family Office's ANIP Position: Q3 2022 in Review

Collective Family Office sold out of ANI Pharmaceuticals (ANIP) in Q3 2022, closing a stake of 7,182 shares — an estimated $213K sold.

Collective Family Office first reported a position in ANIP in Q4 2021 and held it in 3 quarters. The position peaked at $241K in Q4 2021. 126 funds tracked by Wall St. Rank hold ANIP as of Q3 2022.

  • Collective Family Office reported no remaining ANI Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Collective Family Office sold 7,182 ANI Pharmaceuticals shares in Q3 2022, an estimated $213K.
  • Collective Family Office first reported a position in ANI Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Collective Family Office's ANI Pharmaceuticals position peaked at $241K in Q4 2021.
  • 126 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2022.

Based on Collective Family Office's 13F filing for Q3 2022, filed 14 Oct 2022.